GALT
NASDAQ
$4
Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $11 (+175.00%)
Market Cap
$313M
Free Cash Flow Yield
-6.40%
Beta (5Y)
0.59
Price Chart
Valuation
Market Cap$313M
Forward P/E4.54
P/B207.70
Profitability
EBITDA-$19M
EPS-$0.41
Financial Health
Free Cash Flow Yield-6.40%
Growth & Risk
EPS 5Y CAGR-2.50%
FCF 5Y CAGR-2.37%
Beta (5Y)0.59
Sharpe Ratio0.78